Senekowitsch, S.; Freitag, T.; Dubinski, D.; Freiman, T.M.; Maletzki, C.; Hinz, B.
Validation of an LC-MS/MS Method for the Simultaneous Intracellular Quantification of the CDK4/6 Inhibitor Abemaciclib and the EZH2 Inhibitors GSK126 and Tazemetostat. Pharmaceutics 2025, 17, 433.
https://doi.org/10.3390/pharmaceutics17040433
AMA Style
Senekowitsch S, Freitag T, Dubinski D, Freiman TM, Maletzki C, Hinz B.
Validation of an LC-MS/MS Method for the Simultaneous Intracellular Quantification of the CDK4/6 Inhibitor Abemaciclib and the EZH2 Inhibitors GSK126 and Tazemetostat. Pharmaceutics. 2025; 17(4):433.
https://doi.org/10.3390/pharmaceutics17040433
Chicago/Turabian Style
Senekowitsch, Stefan, Thomas Freitag, Daniel Dubinski, Thomas M. Freiman, Claudia Maletzki, and Burkhard Hinz.
2025. "Validation of an LC-MS/MS Method for the Simultaneous Intracellular Quantification of the CDK4/6 Inhibitor Abemaciclib and the EZH2 Inhibitors GSK126 and Tazemetostat" Pharmaceutics 17, no. 4: 433.
https://doi.org/10.3390/pharmaceutics17040433
APA Style
Senekowitsch, S., Freitag, T., Dubinski, D., Freiman, T. M., Maletzki, C., & Hinz, B.
(2025). Validation of an LC-MS/MS Method for the Simultaneous Intracellular Quantification of the CDK4/6 Inhibitor Abemaciclib and the EZH2 Inhibitors GSK126 and Tazemetostat. Pharmaceutics, 17(4), 433.
https://doi.org/10.3390/pharmaceutics17040433